Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Arena Pharmaceutical (ARNA)

39.69 0.42 (1.07%)

04-20 16:00

Open:

39.39

Pre. Close:

39.27

High:

39.82

Low:

38.821

Volume:

716,391

Market Cap:

1947M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

39.824 - 39.963

39.963 - 40.09

Low:

38.42 - 38.599

38.599 - 38.763

Close:

39.404 - 39.656

39.656 - 39.886

Technical analysis  (as of: 2018-04-20 4:27:32 PM)

Overall:

      

Stoxline posted a BUY today, same as yesterday. This stock seems to continue bullish move. If you bought, continue to hold stock until SELL signal. You are relatively safe to buy now, upward move is expected.

Target:

Six months: 53.55     One year: 62.55

Support:

Support1: 36.05    Support2: 30.00

Resistance:

Resistance1: 45.85    Resistance2: 53.55

Pivot:

36.51

Moving Averages:

MA(5): 37.89     MA(20): 37.49

MA(100): 36.68     MA(250): 27.26

MACD:

MACD(12,26): -0.15     Signal(12,26,9): -0.60

%K %D:

%K(14,3): 85.09     %D(3): 66.16

RSI:

RSI(14): 55.87

52-Week:

High: 45.85  Low: 11.3  Change(%): 191.8

Average Vol(K):

3-Month: 138109  10-Days 111211

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
ARNA has closed below upper band by 3.3%. Bollinger Bands are 19.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2018-04-19T12:04:52-04:00
Q2 2018 Biotech Catalyst Watchlist: Phase 2 Clinical Trials

2018-04-12T08:30:00-04:00
Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting

2018-03-28T18:55:28-04:00
Institutional Top Ideas Series: Deerfield Management

2018-03-26T16:15:00-04:00
Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares

2018-03-26T08:07:28-04:00
Arena's APD371 For $14 Billion Dollar Pain Market

2018-03-24T01:55:21-04:00
Novo Nordisk Can Succeed In Weight Loss Where Orexigen, Vivus, Arena Failed

2018-03-23T19:30:00-04:00
Arena Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27

2018-03-22T09:24:00-04:00
Premarket Losers as of 9:05 am (03/22/2018)

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Biotechnology Medical Research

Shares Out. (M)

49.18

Shares Float (M)

46.45

% Held by Insiders

6.90

% Held by Institutions

59.50

Shares Short (K)

3193

Shares Short Prior Month (K)

2680

Stock Financials

EPS

-2.680

EPS Est. Current Year

-2.940

EPS Est. Next Year

-2.730

EPS Est. Next Quarter

-0.660

Forward EPS

-3.319

Book Value (p.s.)

8.470

PEG Ratio

0.61

Profit Margin

Operating Margin

-374.90

Return on Assets (ttm)

-36.0

Return on Equity (ttm)

-74.0

Qtrly Rev. Growth

-82.0

Gross Profit (p.s.)

0.246

Sales Per Share

EBITDA (p.s.)

-1.397

Qtrly Earnings Growth

Operating Cash Flow (M)

-66.64

Levered Free Cash Flow (M)

-38.60

atoplab.com

Valuation

P/E

-14.81

P/E Growth Ratio

0.01

P/BV

4.69

P/S

2995678976.00

P/CF

-29.29

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

2017-06-19

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.